Partial Response to Nivolumab and Ipilimumab in a Patient With Malignant Pleural Mesothelioma and Pre‐Existing Myasthenia Gravis Without Severe Flares or Immune‐Related Adverse Events: A Case Report

• Published in: Respirology case reports Vol. 13; no. 8
• Main Authors: Higa, Mariko, Kuda, Tomoya, Ohya, Yuichiro, Kawasaki, Hidenori
• Format: Journal Article
• Language: English
• Published: Chichester, UK John Wiley & Sons, Ltd 01.08.2025; John Wiley & Sons, Inc
• Subjects: Asymptomatic; Autoimmune diseases; Case Report; Case reports; Chemotherapy; Combination therapy; Disease; disease flares; Immune checkpoint inhibitors; immune‐related adverse events; ipilimumab; Kinases; Medical prognosis; Mesothelioma; Myasthenia gravis; Myocarditis; Neurology; nivolumab; Patients; pre‐existing myasthenia gravis; Remission (Medicine); Steroids

ABSTRACT Detailed clinical data on the combination immune checkpoint inhibitor (ICI) therapy in patients with myasthenia gravis (MG) remain limited. We report a case of malignant pleural mesothelioma with previously undiagnosed ocular MG. Owing to hepatic dysfunction, reduced doses of nivolumab and...